Cover Image
市場調查報告書

細胞週期蛋白依賴性激酶4:開發中產品分析

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 367821
出版日期 內容資訊 英文 123 Pages
訂單完成後即時交付
價格
Back to Top
細胞週期蛋白依賴性激酶4:開發中產品分析 Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H1 2018
出版日期: 2018年05月16日 內容資訊: 英文 123 Pages
簡介

本報告提供以細胞週期蛋白依賴性激酶4為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

細胞週期蛋白依賴性激酶4 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Beta Pharma Inc
  • Eli Lilly and Company
  • FLX Bio Inc
  • G1 Therapeutics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Novartis AG
  • Onconova Therapeutics Inc
  • Pfizer Inc
  • TEIJIN FIBERS製藥
  • Tiziana Life Sciences Plc
  • ViroStatics srl
  • XuanZhu Pharma Co Ltd

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1453TDB

Summary:

According to the recently published report 'Cyclin Dependent Kinase 4 - Pipeline Review, H1 2018'; Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.

The report 'Cyclin Dependent Kinase 4 - Pipeline Review, H1 2018' outlays comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 4, 2, 1, 9, 1 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Immunology and Toxicology which include indications Metastatic Breast Cancer, Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Mantle Cell Lymphoma, Pancreatic Cancer, Bladder Cancer, Gastric Cancer, Colon Cancer, Esophageal Cancer, Glioblastoma Multiforme (GBM), Leukemias, Liposarcoma, Lymphoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Oligodendroglioma, Pancreatic Ductal Adenocarcinoma, Recurrent Glioblastoma Multiforme (GBM), Solid Tumor, Thymic Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), AIDS - Related Cancer, Anaplastic Oligoastrocytoma, Astrocytoma, B-Cell Leukemia, Brain Tumor, Cervical Cancer, Chemotherapy Induced Myelosuppression, Chordoma, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Duodenal Cancer, Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Fallopian Tube Cancer, Germ Cell Tumors, Glioma, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Neuroendocrine Tumors, Nonmelanomatous Skin Cancer, Peritoneal Cancer, Primary CNS Lymphoma, Prostate Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Thymoma (Thymic Epithelial Tumor) and Unspecified B-Cell Lymphomas.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
  • The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Overview
    • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
    • Beta Pharma Inc
    • Eli Lilly and Co
    • G1 Therapeutics Inc
    • Jiangsu Hengrui Medicine Co Ltd
    • MEI Pharma Inc
    • MetaMax Ltd
    • Novartis AG
    • Onconova Therapeutics Inc
    • Pfizer Inc
    • Sihuan Pharmaceutical Holdings Group Ltd
    • Teijin Pharma Ltd
    • Tiziana Life Sciences Plc
    • ViroStatics srl
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Drug Profiles
    • abemaciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BEBT-209 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BPI-1178 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-1T38 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GZ-381 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HEC-80797 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • milciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MMD-37K - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ON-123300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palbociclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ribociclib succinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHR-6390 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK4 and CDK6 for Colorectal Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK4 and CDK6 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRX-3177 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trilaciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • voruciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VS-2370 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XZP-3287 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Products
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products
  • Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Product Development Milestones
    • Featured News & Press Releases
      • May 02, 2018: Health Canada approves KISQALI for the treatment of HR-positive and HER2-negative metastatic breast cancer in postmenopausal women in combination with letrozole as an initial endocrine-based therapy
      • Apr 19, 2018: Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting
      • Apr 17, 2018: Positive results with DiviTum from new Pfizer study presented at the AACR congress
      • Apr 16, 2018: G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer
      • Apr 09, 2018: Tiziana Life Sciences Announces a Poster Presentation on Phase II clinical data with Milciclib in Thymic carcinoma and Thymoma patients at the American Society of Clinical Oncology (ASCO) Meeting (June 1-5, Chicago IL)
      • Apr 09, 2018: G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitor Trilaciclib at the 2018 American Association for Cancer Research (AACR) Annual Meeting
      • Apr 09, 2018: G1 Therapeutics to Present Preclinical Data on G1T38 at the 2018 American Association for Cancer Research (AACR) Annual Meeting
      • Mar 15, 2018: Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American Association for Cancer Research Annual Meeting 2018
      • Mar 12, 2018: Novartis' Advanced Breast Cancer Drug Kisqali (ribociclib) Recommended for NHS Funding in Scotland, Offering Women an Average of two Years without their Disease Getting Worse
      • Mar 12, 2018: Novartis's Kisqali accepted for use in NHS Scotland
      • Mar 05, 2018: G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Benefits in Patients with Small Cell Lung Cancer
      • Mar 01, 2018: New blood test could quickly predict if the drug palbociclib will help breast cancer patients
      • Feb 26, 2018: Lilly Receives Additional FDA Approval for Verzenio (abemaciclib), as Initial Treatment for Advanced Breast Cancer
      • Feb 22, 2018: Leading US University Includes DiviTum in a New Study of Breast Cancer with Ibrance
      • Feb 15, 2018: Quebec and New Brunswick Become First Provinces to Provide Public Funding of IBRANCE for the First-Line Treatment of Metastatic Breast Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..6), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Beta Pharma Inc, H1 2018
  • Pipeline by Eli Lilly and Co, H1 2018
  • Pipeline by G1 Therapeutics Inc, H1 2018
  • Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
  • Pipeline by MEI Pharma Inc, H1 2018
  • Pipeline by MetaMax Ltd, H1 2018
  • Pipeline by Novartis AG, H1 2018
  • Pipeline by Onconova Therapeutics Inc, H1 2018
  • Pipeline by Pfizer Inc, H1 2018
  • Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, H1 2018
  • Pipeline by Teijin Pharma Ltd, H1 2018
  • Pipeline by Tiziana Life Sciences Plc, H1 2018
  • Pipeline by ViroStatics srl, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Dormant Products, H1 2018 (Contd..2), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top